Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go:
TBC
investment:
Withheld
Genuine Impact is the next generation financial terminal made exclusively to empower DIY investors by providing experts with automation tools, portfolio enhancer, unbiased data and insights. Genuine Impact is more cost-effective in comparison with traditional financial terminals, and it makes financial research effortless and efficient. Currently, the company's beta app has 500+ users from more than 27 countries. With the proceeds, the fund raised will be used for new product development, enhancement of existing product and for marketing and branding.
days to go:
Expired
investment:
£500,920
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
The Gut Stuff is a proactive advocate for gut health, educating a substantial community and offering an innovative app in BETA that aims to bridge gaps in the gut health market. With a strong presence in physical products, workplace education, and media, they're positioned to redefine the gut health category and leverage diversified revenue streams for growth during their expansion into the digital realm.
days to go:
Expired
investment:
£321,662
With the rise of coffee and its many variations, it’s time for tea to take the spotlight. TeaTimed want to rediscover the lost art of creating a great cuppa by controlling the key-variables during the brewing process, to consistently produce a high-quality beverage. TeaTimed aim to re-invent tea from a just a 'service' for customers, to an unforgettable experience.
days to go:
Expired
investment:
£18,290
Bippit is a wellbeing platform that provides employees with financial consultancy from a professional with zero cost to the employees themselves. The company asserts that COVID-19 has made financial consultancy services difficult to access for employees. Bippit aims to resolve this situation. It is available in mobile and desktop formats and integrates with an employees’ entire financial life through 'Open Banking'. Bippit argues that this helps staff members receive all the tools they need to learn, plan, and take action concerning their finances. It also helps companies save time and money, ensures that employees receive an impartial support system, and allows financial experts to get an extra revenue stream. The company will launch an Initial Public Offering (IPO) likely within 5 years if it moves beyond strategic acquisition.
days to go:
Expired
investment:
£73,000
